

Novartis Gene Therapies, a Novartis company, is dedicated to developing and commercializing gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. Founded in 2013 and headquartered in Bannockburn, IL, Novartis Gene Therapies pioneered foundational research, establishing AAV9 as an ideal vector for gene transfer in diseases affecting the central nervous system, laying the groundwork to build a best-in-class, transformational gene therapy pipeline. Novartis Gene Therapies' initial gene therapy for spinal muscular atrophy (SMA) has been approved in many parts of the world including the U.S., Japan, Israel, EU and Brazil. Having provided treatment to more than 1.800 SMA patients worldwide, Novartis Gene Therapies is today one of the world's leading gene therapy companies.